Ohmx is an ISO 13485:2003 registered diagnostics company in Evanston, IL operating research and development laboratories and a manufacturing area located in the technology incubator center at Northwestern University.
Dr. Thomas Meade, who has built a reputation for successfully commercializing innovative clinical diagnostic products, founded Ohmx.
Ohmx intends to bring to market an extensive menu of POCT options for the screening, monitoring, and detection of both acute and chronic diseases. Ohmx is developing an accurate and reliable, low-cost, comprehensive POCT system that quickly quantifies biomarkers from low-volume biological samples.
The go-to-market assay will be Cardiac Troponin-I (cTnI) followed by additional Cardiac markers. Cardiac Troponin-I is a test used to diagnose and treat myocardial infarction and stratify the mortality risk of patients suffering from coronary diseases. The enhanced performance of the Ohmx platform has demonstrated a high sensitivity version of the assay (hs-cTnI).
Ohmx is also developing additional tests for its detection platform. Research indicates that clinicians are receptive to this platform for two reasons: